Importance of genetic cancer risk assessment as a strategy to stratify risk and provide precision prevention in high-risk patients and families.

Ashton-Prolla P; Achatz MIW; Moreira MAM; Palmero EI; Soares DCQ; Ferraz VEF; Caires IQS; Guindalini RSC; Gifoni ACLVC

doi:10.1590/1806-9282.2024s117

Importance of genetic cancer risk assessment as a strategy to stratify risk and provide precision prevention in high-risk patients and families.

Affiliations

1. Hospital de Clínicas de Porto Alegre, Medical Genetics Service - Porto Alegre (RS), Brazil.
Authors
Ashton-Prolla P¹
(1 author)
2. Hospital Sirio-Libanês - São Paulo (SP), Brazil.
Authors
Achatz MIW²
(1 author)
3. Instituto Nacional de Câncer, Genetics Program - Rio de Janeiro (RJ), Brazil.
Authors
Moreira MAM³
Palmero EI³
(2 authors)
4. Real Hospital Português, Oncogenetics Service - Recife (PE), Brazil.
Authors
Soares DCQ⁴
(1 author)
5. Universidade de São Paulo, Faculty of Medicine of Ribeirão Preto, Department of Genetics - Ribeirão Preto (SP), Brazil.
Authors
Ferraz VEF⁵
(1 author)

Show all (6)

ORCIDs linked to this article

Show all (9)

Revista da Associacao Medica Brasileira (1992), 07 Jun 2024, 70(suppl 1):e2024S117
https://doi.org/10.1590/1806-9282.2024s117 PMID: 38865537

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1590/1806-9282.2024s117

References

Articles referenced by this article (19)

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B; National Surgical Adjuvant Breast and Bowel Project
JAMA, (18):2251-2256 2001
MED: 11710890
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Sessa C, Balmana J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S; ESMO Guidelines Committee. Electronic address: [email protected]
Ann Oncol, (1):33-47 2022
MED: 36307055
Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.
Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, Grisham RN, Long Roche K, Frey MK, Chi DS, Abu-Rustum N, Aghajanian C, Offit K, Stadler ZK
JCO Oncol Pract, (3):201-209 2021
MED: 34582274
Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi J, Del Pilar Estevez Diz M, Stock S, Muller D
Appl Health Econ Health Policy, (1):97-109 2021
MED: 32537695
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R
JAMA Oncol, (12):1718-1730 2019
MED: 31580391
Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, Lopez RVM, Zheng Y, Freitas E, Monteiro FPM, Valim A, Schlesinger D, Kok F, Olopade OI, Folgueira MAAK
Sci Rep, (1):4190 2022
MED: 35264596
The Inherited p53 Mutation in the Brazilian Population.
Achatz MI, Zambetti GP
Cold Spring Harb Perspect Med, (12):a026195 2016
MED: 27663983
Clinicopathological and molecular characterization of Brazilian families at risk for Lynch syndrome.
de Paula AE, Galvao HCR, Bonatelli M, Sabato C, Fernandes GC, Berardinelli GN, Andrade CEM, Neto MC, Romagnolo LGC, Campacci N, Scapulatempo-Neto C, Reis RM, Palmero EI
Cancer Genet, 82-91 2021
MED: 33647816
PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN
Target Oncol, (4):471-503 2023
MED: 37268756
The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway.
Asphaug L, Melberg HO
MDM Policy Pract, (1):2381468318821103 2019
MED: 30746499

Show 9 more references (10 of 19)

Search life-sciences literature (45,103,589 articles, preprints and more)

Importance of genetic cancer risk assessment as a strategy to stratify risk and provide precision prevention in high-risk patients and families.

Affiliations

Authors

Authors

Authors

Authors

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.

Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.

The Inherited p53 Mutation in the Brazilian Population.

Clinicopathological and molecular characterization of Brazilian families at risk for Lynch syndrome.

PARP Inhibitors in Ovarian Cancer: A Review.

The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway.

Similar Articles

Genetic predisposition testing for cancer: effects on families' lives.

Cancer risk assessment and cancer prevention: promises and challenges.

Are we ready to screen for inherited susceptibility to cancer?

Population-based Genetic Testing for Precision Prevention.

Partnerships & funding

Similar Articles

Genetic predisposition testing for cancer: effects on families' lives.
Holist Nurs Pract, 12(3):9-19, 01 Apr 1998

Cancer risk assessment and cancer prevention: promises and challenges.
Cancer Prev Res (Phila), 1(4):229-232, 01 Sep 2008

Are we ready to screen for inherited susceptibility to cancer?
Oncology (Williston Park), 10(1):57-64; discussion 67, 01 Jan 1996

Population-based Genetic Testing for Precision Prevention.
Cancer Prev Res (Phila), 13(8):643-648, 14 May 2020

Search life-sciences literature (45,103,589 articles, preprints and more)

Importance of genetic cancer risk assessment as a strategy to stratify risk and provide precision prevention in high-risk patients and families.

Author information

Affiliations

Authors

Authors

Authors

Authors

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Similar Articles

Partnerships & funding